首页> 外文期刊>JMIR Medical Informatics >A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non–Vitamin K Antagonist Oral Anticoagulants and Warfarin
【24h】

A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non–Vitamin K Antagonist Oral Anticoagulants and Warfarin

机译:基于网络的临床队列系统,用于特定临床有效性和安全性结果的队列监测:非维生素K拮抗剂口服抗凝剂和华法林的队列研究

获取原文
           

摘要

Background Conventional systems of drug surveillance lack a seamless workflow, which makes it crucial to have an active drug surveillance system that proactively assesses adverse drug events. Objective The aim of this study was to develop a seamless, Web-based workflow for comparing the safety and effectiveness of drugs in a database of electronic medical records. Methods We proposed a comprehensive integration process for cohort surveillance using the National Taiwan University Hospital Clinical Surveillance System (NCSS). We studied a practical application of the NCSS that evaluates the drug safety and effectiveness of novel oral anticoagulants (NOACs) and warfarin by cohort tree analysis in an efficient and interoperable platform. Results We demonstrated a practical example of investigating the differences in effectiveness and safety between NOACs and warfarin in patients with nonvalvular atrial fibrillation (AF) using the NCSS. We efficiently identified 2357 patients with nonvalvular AF with newly prescribed oral anticoagulants between 2010 and 2015 and further developed 1 main cohort and 2 subcohorts for separately measuring ischemic stroke as the clinical effectiveness outcome and intracranial hemorrhage (ICH) as the safety outcome. In the subcohort of ischemic stroke, NOAC users exhibited a significantly lower risk of ischemic stroke than warfarin users after adjusting for age, sex, comorbidity, and comedication in an intention-to-treat (ITT) analysis ( P =.01) but did not exhibit a significantly distinct risk in an as-treated (AT) analysis ( P =.12) after the 2-year follow-up. In the subcohort of ICH, NOAC users did not exhibit a different risk of ICH both in ITT ( P =.68) and AT analyses ( P =.15). Conclusions With a seamless and Web-based workflow, the NCSS can serve the critical role of forming associations between evidence and the real world at a medical center in Taiwan.
机译:背景技术常规的药物监视系统缺乏无缝的工作流程,这使得拥有主动评估不良药物事件的主动药物监视系统至关重要。目的这项研究的目的是开发一个无缝的,基于Web的工作流,以比较电子病历数据库中药物的安全性和有效性。方法我们提出了使用国立台湾大学医院临床监视系统(NCSS)进行队列监视的综合集成过程。我们研究了NCSS的实际应用,该应用通过在有效且可互操作的平台中进行的队列分析来评估新型口服抗凝剂(NOAC)和华法林的药物安全性和有效性。结果我们展示了一个使用NCSS研究非瓣膜性房颤(AF)患者NOAC和华法林之间有效性和安全性差异的实际例子。我们在2010年至2015年期间有效地确定了2357例非瓣膜性房颤患者并新开了口服抗凝药,并进一步开发了1个主要队列和2个亚队列,分别将缺血性卒中作为临床有效性结果,将颅内出血(ICH)作为安全性结果。在缺血性卒中亚组中,经过年龄,性别,合并症和喜剧调整后的意向性治疗(ITT)分析后,NOAC使用者的缺血性卒中风险明显低于华法林使用者(P = .01),但在随访2年后,经治疗(AT)分析未显示明显不同的风险(P = .12)。在ICH的亚人群中,NOAC用户在ITT(P = .68)和AT分析(P = .15)中均未显示出ICH的其他风险。结论NCSS通过一个无缝的基于Web的工作流,可以在台湾医疗中心的证据与现实世界之间建立联系方面发挥关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号